Welcome to our dedicated page for Verastem news (Ticker: VSTM), a resource for investors and traders seeking the latest updates and insights on Verastem stock.
Verastem, Inc. (NASDAQ: VSTM) is a pioneering biopharmaceutical company dedicated to discovering and developing innovative drugs that target cancer stem cells. These cells are a significant factor in tumor recurrence and metastasis, posing a substantial challenge in the treatment of various cancers. Verastem's mission is to translate groundbreaking cancer stem cell research into new medicines that address major cancers, including breast cancer.
The core focus of Verastem lies in advancing novel anticancer agents, particularly those inhibiting critical signaling pathways that promote cancer cell survival and tumor growth. This includes the development of RAF/MEK inhibitors and FAK inhibitors. These targeted therapies are designed to intercept the mechanisms that allow cancer cells to thrive and spread, offering hope for more effective treatments.
One of the company's notable projects involves the combination of avutometinib (a RAF/MEK clamp) and defactinib (a FAK inhibitor). This drug combination has shown promising results and has been granted breakthrough therapy designation for treating recurrent low-grade serous ovarian cancer (LGSOC), regardless of KRAS status, after one or more prior lines of therapy, including platinum-based chemotherapy.
Verastem has also entered into a strategic partnership with GenFleet Therapeutics, a clinical-stage biotechnology company. This collaboration aims to advance three oncology programs, with GFH375 being the first selected candidate. GFH375, an oral KRAS G12D inhibitor, targets both the
Verastem Oncology (Nasdaq: VSTM) announced its management team's upcoming participation in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference. The presentation is scheduled for Tuesday, December 3rd at 11:15 am EST.
The event will be accessible through a live webcast under the 'Events & Presentations' section of Verastem's website. A replay will remain available on the website for approximately 90 days after the presentation.
Verastem Oncology (Nasdaq: VSTM) reported its Q3 2024 financial results and highlighted recent business updates. The company completed the rolling NDA submission for the avutometinib and defactinib combination in recurrent KRAS mutant low-grade serous ovarian cancer (LGSOC) in October 2024. They seek accelerated approval and priority review, with an FDA decision expected by the end of 2024 and potential approval by mid-2025. Verastem presented positive data from the RAMP 201 trial at IGCS 2024, showing robust response rates and low discontinuation due to adverse events. Financially, the company ended Q3 2024 with $113.2 million in cash and equivalents, providing a runway through mid-2025. Total operating expenses were $37.0 million, up from $21.3 million in Q3 2023, driven by increased R&D and SG&A costs. The net loss for Q3 2024 was $24.0 million, or $0.60 per share, compared to $20.0 million, or $0.75 per share, in Q3 2023.
Verastem Oncology (VSTM) has completed its rolling New Drug Application (NDA) to the FDA for avutometinib plus defactinib combination therapy for adults with recurrent KRAS mutant low-grade serous ovarian cancer (LGSOC). The company is seeking accelerated approval and priority review, with a potential FDA approval decision by mid-2025. The Phase 2 RAMP 201 study showed promising results with a 44% confirmed overall response rate, 22 months median progression-free survival, and 70% disease control rate at 6 months in KRAS mutant LGSOC patients. If approved, this would be the first FDA-approved treatment specifically for this rare cancer type.
Verastem Oncology (Nasdaq: VSTM) has announced its management team's upcoming participation in two major investor conferences. The company will attend the 2024 Truist Securities BioPharma Symposium on November 7 and participate in a fireside chat at the 2024 Guggenheim Healthcare Innovation Conference on November 13 at 9:00 am EDT.
The fireside chat will be accessible via live webcast in the Events & Presentations section of Verastem's website, with a replay available for approximately 90 days post-presentation.
Verastem Oncology presented updated data from the Phase 2 RAMP 201 trial evaluating avutometinib and defactinib combination in recurrent low-grade serous ovarian cancer (LGSOC) at the IGCS 2024 Annual Meeting. Key findings include:
- 31% overall response rate (44% in KRAS mutant, 17% in KRAS wild-type)
- Median progression-free survival of 12.9 months (22 months in KRAS mutant)
- Disease control rate at 6+ months: 61% overall (70% KRAS mutant, 50% KRAS wild-type)
- Generally well-tolerated with 10% discontinuation rate due to adverse events
Verastem plans to complete NDA submission in October 2024 for adult patients with recurrent KRAS mutant LGSOC, seeking Accelerated Approval and Priority Review from the FDA. The company aims to bring the first FDA-approved treatment for this specific indication to market in 2025.
Verastem Oncology (Nasdaq: VSTM) announced details for its late-breaking presentation of mature data from the ongoing Phase 2 RAMP 201 clinical trial at the International Gynecologic Cancer Society (IGCS) Annual Global Meeting in Dublin, Ireland. The presentation, scheduled for October 17, 2024, at 11:42 AM ET, will include updated safety and efficacy data on the combination of avutometinib and defactinib in patients with recurrent low-grade serous ovarian cancer (LGSOC).
The company will host an investor conference call and webcast on the same day at 4:30 PM EDT to review the trial data. The presentation will cover overall response rate, progression-free survival, and duration of response. Professor Susana N. Banerjee, the global lead investigator, will present the findings.
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company focused on developing new cancer medicines, has announced the grant of stock options to nine new employees. These options allow the purchase of 109,000 shares of common stock at an exercise price of $2.82 per share, which was the closing price on October 1, 2024.
The grants were made under the Nasdaq inducement grant exception, in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options will vest over four years, with 25% vesting on the one-year anniversary of each employee's hire date, and the remaining shares vesting quarterly over the following three years in equal amounts. Vesting is contingent on continued employment or service provision to Verastem Oncology.
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company focused on developing new cancer medicines, has announced its participation in the 2024 Cantor Global Healthcare Conference. The company's management team will engage in a fireside chat on Wednesday, September 18 at 3:40 pm EDT.
Interested parties can access a live webcast of the discussion through the 'Events & Presentations' section of Verastem's website. For those unable to attend live, a replay of the webcast will be available on the company's website for approximately 90 days following the presentation.
Verastem Oncology (VSTM) announced the acceptance of a late-breaking abstract for oral presentation at the International Gynecologic Cancer Society (IGCS) Annual Meeting in October 2024. The presentation will feature mature data from the Phase 2 RAMP 201 clinical trial, evaluating the combination of avutometinib (RAF/MEK clamp) and defactinib (FAK inhibitor) in patients with low-grade serous ovarian cancer (LGSOC).
The presentation will include updated safety and efficacy data, including overall response rate, progression-free survival, and duration of response. Verastem Oncology's CEO, Dan Paterson, highlighted that the robust interim data from RAMP 201 enabled the initiation of a rolling NDA submission to the FDA. The company remains on track to complete its NDA submission in Q4 2024.
Verastem Oncology (NASDAQ: VSTM) and STAAR Ovarian Cancer Foundation have established the first Low-Grade Serous Ovarian Cancer (LGSOC) Awareness Day on September 9, 2024. LGSOC is a rare ovarian cancer often affecting younger women, with no FDA-approved treatments. The initiative aims to educate about LGSOC symptoms, provide resources, and advocate for more research.
Key points:
- Approximately 80% of LGSOC patients experience cancer recurrence
- 99% of surveyed patients had no awareness of LGSOC prior to diagnosis
- 60% felt their healthcare provider was not very knowledgeable about LGSOC
- Verastem is conducting clinical trials for an investigational treatment combination for LGSOC
- The company has initiated a rolling new drug application with the FDA for a potential LGSOC-specific treatment
FAQ
What is the current stock price of Verastem (VSTM)?
What is the market cap of Verastem (VSTM)?
What does Verastem, Inc. specialize in?
What are some of Verastem's key projects?
Who are Verastem's partners?
What is GFH375?
What makes Verastem's approach unique?
What are RAF/MEK and FAK inhibitors?
What types of cancer is Verastem targeting?
What recent achievements has Verastem made?
How does Verastem's partnership with GenFleet Therapeutics benefit their research?
Where can I find more information about Verastem, Inc.?
